It is only three years ago that Merck & Co. Inc. got its first approval for Keytruda (pembrolizumab) in melanoma and data presented at the European Society for Medical Oncology congress in Madrid has highlighted how dominant the PD-1 inhibitor has become in such a short space of time.
Speaking to Scrip at the congress, Roger Dansey, head of the company’s clinical development in oncology, noted the huge amount...






